Aligos Therapeutics presents positive data at AASLD Liver Meeting® 2023 demonstrating that treatment with ALG-000184 (CAM-E) significantly reduces hepatitis B antigens (HBsAg, HBcrAg and HBeAg)
Aligos Therapy Hepatitis B virus and antigen-positive (HBeAg+) subjects took 300 mg ALG-000184 once daily + Treatment with entecavir for up to 48 weeks demonstrated: Dose-dependent mean reduction up to 2 log10 IU/mL of HBV antigen Average DNA reduction up to 6.8 log10 International units/ml … Read more